Sanara MedTech Q3 revenue $16M (record), net loss narrows to $1.1M, Adj. EBITDA positive $0.3M

Sanara MedTech Inc.

2023-Q3 EPS reported -$0.49 revenue$47,300,029

Q3 net revenue $16.0M, up 23% YoY; net loss $1.1M vs $1.5M loss a year ago.
Adjusted EBITDA positive $0.3M vs negative $1.6M in Q3 2022.
Acquired certain collagen assets (CellerateRX, HYCOL) in August, eliminating future royalties.
First sales of ALLOCYTE Plus and BIASURGE completed post-quarter; supply issues for ALLOCYTE resolved.
Twelve new sales reps hired in 9M 2023; products sold in over 1,000 facilities across 32 states.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sanara MedTech Inc. reported the quarter ended September 30, 2023 results: revenue $16.0 million, net income net loss of $1.1 million.

Period: the quarter ended September 30, 2023
Revenue: $16.0 million
Net income: net loss of $1.1 million
Result: reported results

Exact text from the filing

that can improve outcomes while reducing healthcare expenditures.” Third Quarter 2023 Strategic and Operational Highlights (Unaudited) ● The Company generated net revenue of $16.0 million for the three months ended September 30, 2023, an eighth consecutive record sales quarter. ● The Company’s loss before income taxes for the three months ended September 30,

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.